Lysergic acid diethylamide
- Generic Name
- Lysergic acid diethylamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25N3O
- CAS Number
- 50-37-3
- Unique Ingredient Identifier
- 8NA5SWF92O
- Background
Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.
- Associated Conditions
- -
- Associated Therapies
- -
Lysergic acid diethylamide by Mind Medicine MindMed for Generalized Anxiety Disorder (GAD)
GlobalData evaluates drug development stages using historical data, focusing on Lysergic acid diethylamide for anxiety and depression, targeting 5HT2A receptor. MindMed develops treatments for brain health disorders, including psychedelic drugs, based in New York.
Lysergic acid diethylamide by Mind Medicine MindMed for Major Depressive Disorder
GlobalData evaluates drug development stages using historical data, focusing on Lysergic acid diethylamide for anxiety and depression. MindMed develops treatments for brain health disorders, utilizing psychedelic drugs and clinical trials.
Most Read Stories From 2024
Know Labs announced a wearable, non-invasive continuous glucose monitor called KnowU with AI and machine learning capabilities. TherVacB, a therapeutic vaccine for chronic hepatitis B, entered its first in-human trial. Dynavax initiated a phase 1/2 trial for Z-1018, a herpes zoster vaccine. The FDA cleared the twiist Automated Insulin Delivery System for type 1 diabetes. Additionally, the FDA granted breakthrough therapy designation to LSD for treating generalized anxiety disorder.
MindMed launches first Phase III LSD trial; A new psychedelic mushroom species?
MindMed begins Phase III LSD trial for anxiety disorder without psychotherapy; researchers identify new psychedelic mushroom species, Psilocybe ochraceocentrata; Denver recommends indoor psilocybin sessions; study shows psilocybin increases empathy in depressed individuals without improving depression; Naropa University spins out psychedelic training program.
First Patient Dosed in Phase 3 Study of Psychedelic MM120 in Generalized Anxiety Disorder
MindMed dosed the first patient in a phase 3 trial of LSD for generalized anxiety disorder (GAD). The 52-week study will enroll 200 participants, with a randomized, double-blind, placebo-controlled period for the first 12 weeks, followed by an open-label extension. MM120, a synthetic ergotamine, incorporates fast-dissolve technology and has received FDA Breakthrough Therapy Designation for GAD. If approved, it would be the first GAD treatment since 1987.
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in ...
MindMed initiates Phase 3 Voyage study of MM120 ODT (LSD) for GAD, with primary endpoint measuring HAM-A score change at week 12. The study builds on positive Phase 2b results and anticipates topline data in H1 2026. A second Phase 3 trial, Panorama, is set to begin in H1 2025.
Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment
MindMed (NASDAQ:MNMD), a $525M clinical-stage biopharmaceutical company, focuses on MM120, a LSD-based compound for Generalized Anxiety Disorder (GAD). MM120 showed significant Phase 2b trial benefits, with rapid onset and sustained effects. The FDA's Breakthrough Therapy Designation for MM120 could accelerate its development. Analysts project potential U.S. sales of $1.6B, with MM120 addressing a large, underserved GAD market. However, challenges include patient adoption, regulatory hurdles, and commercialization of psychedelic therapies.
Police arrest 7 in Rutgers U. social media drug ring bust
Seven people connected to a private social media drug network serving Rutgers University students were arrested in New Jersey. The operation, 'Operation RU Pharm,' led by the Middlesex County Prosecutor's Office Narcotics Task Force, recovered drugs, cash, and a firearm. The network, operated by a former Rutgers student, allowed students to browse drug menus and negotiate purchases.
The promise of the psychedelic revolution
Recent studies show psilocybin can treat severe depression and PTSD by promoting neuroplasticity. Peter Silverstone, a psychopharmacology expert, highlights psychedelics' potential as a mental health breakthrough. Despite risks, supervised use shows promise, with Alberta leading in psychedelic therapy regulation and insurance coverage. Caution is advised due to potential risks and hype.
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
The podcast discusses the psychedelics industry's current state, focusing on clinical trials for psilocybin therapies by companies like Compass Pathways and Cybin. Despite reduced investor interest due to hype and regulatory challenges, positive phase 3 trial results could reignite investment. The industry faces unique hurdles, including legal and testing complexities, but companies are innovating with patents and different therapeutic approaches.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath